



**Late Dr. J. C. Patel**  
Founder Editor  
Editor (1947-2003)

**Editor-in-Chief**  
**Dr. B. C. Mehta**

**Editor**  
**Dr. D. K. Sahu**

**Correspondence:**  
**Dr. D. K. Sahu**  
A-109, Kanara Business  
Center, Off Link Road,  
Ghatkopar (E),  
Mumbai - 400075, India.  
Tel: 22-66491818/1816  
Fax: 22-66491817  
E-mail: ijms@medknow.com

**Dr. B. C. Mehta**  
Flat No. 504, Prachi Society,  
Juhu-Versova Link Road,  
Andheri (W),  
Mumbai 400 053

**Manuscript submission:**  
**<http://journalonweb.com>**

**Free full text at:**  
**[www.indianjmedsci.org](http://www.indianjmedsci.org)**  
**[www.bioline.org.br/ms](http://www.bioline.org.br/ms)**

## Indian Journal of Medical Sciences

ISSN 0019-5359

**Indian Journal of Medical Sciences** is a monthly journal published as a medium for the advancement of scientific knowledge in all the branches of Medicine and allied Sciences and publication of scientific investigation in these fields. It is also indented to present this as a form suitable to the general practitioner and primary care physician.

The journal is owned by the **Indian Journal of Medical Sciences Trust**, a registered charitable organisation and published by Medknow Publications, Mumbai, India.

The journal is **indexed/listed** with Index Medicus (Indian J Med Sci), MEDLINE, PubMed, EMBASE, CAB Abstracts, Global Health, Health and Wellness Research Center, Health Reference Center Academic, InfoTrac One File, Expanded Academic ASAP, Journal Articles Database (JADE), Indian Science Abstracts and PubList.

**All the rights are reserved.** Apart from any fair dealing for the purposes of research or private study, or criticism or review, no part of the publication can be reproduced, stored, or transmitted, in any form or by any means, without the prior permission of the Editor, Indian Journal of Medical Sciences.

The information and opinions presented in the Journal reflect the views of the authors and not of the Indian Journal of Medical Sciences Trust or the Editorial Board. Publication does not constitute endorsement by the journal.

Indian Journal of Medical Sciences and/or its publisher cannot be held responsible for errors or for any consequences arising from the use of the information contained in this journal. The appearance of advertising or product information in the various sections in the journal does not constitute an endorsement or approval by the journal and/or its publisher of the quality or value of the said product or of claims made for it by its manufacturer.

Trademarks Acknowledged

# INDIAN JOURNAL OF MEDICAL SCIENCES

VOLUME	61
NUMBER	12
DECEMBER	2007

### EDITORIAL

Specific learning disabilities and attention-deficit hyperactivity disorder: under-recognized in India <i>Susan G. Crawford</i>	637
--	-----

### ORIGINAL CONTRIBUTIONS

Clinical and psychoeducational profile of children with specific learning disability and co-occurring attention-deficit hyperactivity disorder <i>Sunil Karande, Nitin Satam, Madhuri Kulkarni, Rukhshana Sholapurwala, Anita Chitre, Nilesh Shah</i>	639
Association between hepatitis B surface antibody seropositivity and coronary artery disease <i>Alireza Amirzadegan, Gholamreza Davoodi, Mohammad Ali Boroumand, Siroos Darabyan, Maria Raissi Dehkordi, Hamidreza Goodarzynejad</i>	648
Health-risk behaviors related to road safety among adolescent students <i>Rahul Sharma, Vijay L. Grover, S. Chaturvedi</i>	656

### LETTERS TO EDITOR

Significance of antiphospholipid antibodies in patients with bad obstetric history <i>M. N. Mishra, Sapna Gupta, M. K. Gupta</i>	663
Clozapine-induced double incontinence <i>D. N. Mendhekar, H. S. Duggal</i>	665

### PRACTITIONERS' SECTION

Novel phosphodiesterase-5 inhibitors: Current indications and future directions <i>Rashmi Sharma</i>	667
NEWS	000

Published by  
**Medknow Publications**  
A-109, Kanara Business Center, Off Link Road, Ghatkopar (E), Mumbai - 400075, India

## LETTERS TO EDITOR

### SIGNIFICANCE OF ANTIPHOSPHOLIPID ANTIBODIES IN PATIENTS WITH BAD OBSTETRIC HISTORY

Sir,  
Antiphospholipid antibody syndrome (APAS) is an autoimmune condition that may manifest with fetal loss, thrombosis or autoimmune thrombocytopenia. We share here our experience on prevalence of two clinically most relevant antiphospholipid antibodies (APL) – anticardiolipin antibodies (ACL) and lupus anticoagulants (LA) – and the response to treatment with low-dose Aspirin in 120 patients with bad obstetric history. Inclusion criteria for patients were history of three or more spontaneous abortions or/ and two or more stillbirths with a normal embryonic ultrasound at 6-8 weeks of gestation and negative TORCH serology. Controls comprised of 60 healthy women with at least one successful pregnancy and without previous history of abortion- or pregnancy-associated complications. Sample collection and testing was done, as described by Kumar *et al.*,<sup>[1]</sup> after 12 weeks of miscarriage/ stillbirth in nonpregnant state. Statistical analysis of accrued data was done using EpiInfo 6 software. Probability '*P*' values were calculated using chi-square test.

Our results showed that 34/120 (28.3%) and 9/60 (15%) patients tested positive for ACL and LA respectively, which includes three samples that were positive for both as per

Brandt's criteria.<sup>[2]</sup> Clinical and laboratory profile of patients is shown in Table 1. The titer of ACL was higher than 80 GPL units / liter (L) in two patients only. Increasing age and higher number of conceptions were observed to be more frequently associated with APL. Three controls had ACL of IgG isotype in the range 10-14 GPL units/L, but none tested positive for LA. Statistically both LA (*P* = 0.0014) and ACL (*P* = 0.0005) were found to be significantly related to bad obstetrical outcome. During the study period 55% of the women, who were put on aspirin therapy (75 mg/day), conceived and had uneventful delivery.

APAS has emerged as the most important treatable cause of recurrent miscarriage, early onset preeclampsia and of intrauterine growth restriction. Table 2 shows a comparison of this study with some others in contemporary Indian literature. Silver *et al.* found women with IgG A CL >80 GPL/L had 40% fetal death, while women with IgG ACL <40 GPL/L

**Table 1: Shows clinical and laboratory findings in patients with bad obstetric history**

Clinical presentation/ laboratory tests	Number of cases
Recurrent abortions	80
Stillbirths	30
Both	10
Age range and (Mean)	21- 38 (26) years
Conceptions range and (Mean)	2-8 (5)
Anticardiolipin antibodies	34
Immunoglobulin G	28
10-40 GPL units/L	31
> 40 GPL units/L	3
Immunoglobulin M	6
Both	4
Lupus anticoagulants	9
ACL + LA	3
Thrombocytopenia	8

ACL - Anticardiolipin antibodies; LA - Lupus anticoagulants

**Table 2: A comparison of contemporary Indian studies in literature**

Authors	Numbers controls (C) and patients (P)	ACL	LA	Both	Special features
Kumar <i>et al.</i> , <sup>[2]</sup>	Recurrent abortions and controls; 107 each	33/82 (40.2)	11(10.3)	2	Nil
Velayuthaprabhu <i>et al.</i> , <sup>[4]</sup>	Recurrent abortions 155; no controls	62 (45)	Not included		Studied APS antibodies
Srikrishna <i>et al.</i> , <sup>[5]</sup>	Recurrent abortions 72; no controls	10 (21)	2 (4.2)		Cases of SLE and thrombosis
Kaneria <i>et al.</i> , <sup>[6]</sup>	50	14 (28)	6 (12)	3	Cases of BOH
Present study	Recurrent abortions and still births 120 and controls 60	34 (28.3)	9/60	3/120 (15)	(2.5)

ACL – anticardiolipin antibodies; LA – lupus anticoagulants; BOH – bad obstetric history; APS – antiphosphatidylserine antibodies; SLE – systemic lupus erythematosus, Figures in the parentheses are in percentage

had less than 20% fetal wastage.<sup>[3]</sup> In our study, ACL positivity was present in three controls (5%); only two patient samples had titers exceeding 80 GPL units/L. In a study by Srikrishna *et al.* on 72 patients with obstetric complications with high titer (> 80 GPL units/L) in none of the patients.<sup>[5]</sup> Possibly, majority of Indian population with BOH (bad obstetric history) do not produce high titers of ACL. Usually low titers of IgM and IgG ACL are not associated with poor fetal outcome, and there is a legitimate argument for closely monitoring but not arbitrarily treating women with low ACL titers. There is a requirement for studying baseline levels of ACL in Indian population, and more studies are needed in women with BOH with APAS to account for geographical and genetic variations for determining significant levels and deciding whom to treat.

### ACKNOWLEDGMENT

Dr. (Mrs.) Vani Suryam for statistical analysis of the data.

**M. N. MISHRA, SAPNA GUPTA, M. K. GUPTA<sup>1</sup>**  
Department of Pathology, INHS Asvini, Colaba, Mumbai, <sup>1</sup>Department of Pathology, Bombay Hospital, New Marine Lines, Mumbai, India

### Correspondence:

Dr. Mahendra Narain Mishra, Hospital Laboratory,  
166 Military Hospital, C/O56 APO, India.  
E-mail: mnrmishra@hotmail.com

### REFERENCES

1. Kumar KS, Jyothy A, Prakash MS, Rani HS, Reddy PP. Beta2-glycoprotein I dependent anticardiolipin antibodies and lupus anticoagulant in patients with recurrent pregnancy loss. *J Postgrad Med* 2002;48:5-10.
2. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: An update: On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. *Thromb Haemost* 1995;74:1185-90.
3. Silver RM, Porter TF, van Leeuwen I, Jeng G, Scott JR, Branch DW. Anticardiolipin antibodies: Clinical consequences of "low titers". *Obstet Gynaecol* 1996;87:494-500.
4. Velayuthaprabhu S, Archunan G. Evaluation of anticardiolipin antibodies and antiphosphatidylserine antibodies in women with recurrent abortion. *Indian J Med Sci* 2005;59:347-52.
5. Srikrishna A, Sitalakshmi S, Devi S, Damodar P. Antiphospholipid antibodies-our experience. *Indian J Pathol Microbiol* 2004;47:174-7.
6. Kaneria MV, Vishwanathan C. A preliminary study of antiphospholipid antibodies in 50 cases of bad obstetric history. *J Assoc Physicians India* 1999;47:665-7.